Health Trials

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

JY232(JY232) Injection in Relapsed/Refractory Multiple Myeloma

This study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed/refractory multiple myeloma. It is an early exploratory clinical study of the safety, tolerability and initial efficacy of JY232 injection in the treatment of relapsed/refractory multiple myeloma.

Participants needed: 9
Trial details
Phase: Early Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Shenzhen Genocury Biotech Co., Ltd.Updated: Jan 13, 2026Locations: 1
Eligibility criteria

The subject voluntarily signs the informed consent form, is willing and able to... [+4]

The subject's tumor sample (bone marrow) tests positive for B-Cell Maturation An... [+40]

Read more
Status: Recruiting

JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia

This study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed or refractory B cell lymphoma /leukemia. It is an early exploratory clinical study of the safety, tolerability and initial efficacy of JY231 injection in the treatment of relapsed or refractory B cell lymphoma / leukemia.

Participants needed: 20
Trial details
Age: 18-75Biological sex: AllType: InterventionalSponsor: Shenzhen Genocury Biotech Co., Ltd.Updated: May 15, 2025Locations: 1
Eligibility criteria

Subject voluntarily sign informed consent and are willing and able to comply wit... [+27]

Subjects with active cerebrospinal fluid malignant cells or brain metastases, or... [+16]

Read more
Status: Recruiting

JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia

This study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed or refractory B cell lymphoma / leukemia. It is an early exploratory clinical study of the safety, tolerability and initial efficacy of JY231 injection in the treatment of relapsed or refractory B cell lymphoma / leukemia.

Participants needed: 20
Trial details
Age: 18-75Biological sex: AllType: InterventionalSponsor: Shenzhen Genocury Biotech Co., Ltd.Updated: Nov 7, 2024Locations: 1
Eligibility criteria

Subject voluntarily sign informed consent and are willing and able to comply wit... [+26]

Subjects with active cerebrospinal fluid malignant cells or brain metastases, or... [+16]

Read more